secwatch.observer — SEC 8-K summary
======================================

Issuer:     Barinthus Biotherapeutics plc. (BRNS)
CIK:        0001828185
Form:       8-K
Filed at:   2026-02-23T23:59:59+00:00
Accession:  0001104659-26-018283
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Barinthus (BRNS) amends merger with Clywedog: exchange ratios set, timeline extended to June 30, 2026
--------------------------------------------------------------------------------

- Scheme Exchange Ratio set between 0.1 and 0.166667; Merger Exchange Ratio set between 0.000305 and 0.000508.
- Post-closing ownership: Beacon shareholders ~34%, Clywedog stockholders ~66% on fully diluted basis.
- Beacon minimum cash requirements extended to June 30, 2026 ($20.47M); Clywedog minimum to $1M by May 31, 2026.
- Amendment cites unexpected delay from U.S. federal government shutdowns as reason for extended timeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828185/000110465926018283/0001104659-26-018283-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828185/000110465926018283/tm266347d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-018283

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer